DSM Announces Biologics Development and Manufacturing Agreement for Australian Facility

DSM Announces Biologics Development and Manufacturing Agreement for Australian

PR Newswire

PARSIPPANY, N.J., Oct. 24, 2012

PARSIPPANY, N.J., Oct. 24, 2012 /PRNewswire/ -- DSM Pharmaceutical Products,
the custom manufacturing and technology business of Royal DSM (NYSE, Euronext:
DSM KON), announced today that it has signed a biologics contract
manufacturing agreement with Paranta Biosciences Ltd of Melbourne, Australia.

The contract covers the process development and cGMP manufacture by DSM of
Paranta's lead recombinant human protein. This project represents an agreement
for DSM with an Australian customer at their Brisbane facility. Paranta
Biosciences is an early stage drug development company dedicated to developing
and commercializing novel biotherapeutics based on recombinant human
follistatin for the treatment of respiratory diseases.

Alexander Wessels, CEO of DSM Pharmaceutical Products, stated, "Working with
Paranta is an important milestone for DSM to support the local client base
directly from our facility in Australia, expanding our presence in global
regions. Our collaboration with Biopharmaceuticals Australia (BPA), the
Queensland Government and the Australian Commonwealth Government is already
bringing benefits to Australia by providing biopharmaceutical firms local
support and manufacturing expertise."

Ross Barrow, CEO of Paranta Biosciences stated, "Follistatin has been shown to
have great potential in treating a wide range of inflammatory and fibrotic
respiratory diseases, which affect over 300 million people worldwide. Our
selection of DSM as Paranta's biologics manufacturing partner is the
culmination of an extensive global search process spanning more than nine
months. We are looking forward to working with the Groningen and Brisbane
groups of DSM Biologics as we continue the development and manufacturing
scale-up of what we believe will be a truly exciting biotherapeutic."

Karen King, President of DSM Biologics, the business unit of DSM
Pharmaceutical Products operating the Brisbane site, commented "We are proud
to announce that Paranta has selected DSM as its manufacturing and development
provider. DSM will bring over 25 years of experience, a state-of-the-art
facility and an expert team in Brisbane to help drive the success of Paranta's
lead project." In addition to an R&D and manufacturing site in Groningen, The
Netherlands, DSM is building operations in Brisbane, Australia, with the
support of the Governments of Queensland and the Commonwealth. The Brisbane
facility is DSM's blueprint for its 'biologics plant of the future' for the
production of biopharmaceuticals.

"For Biopharmaceuticals Australia, DSM's signing-up Paranta for the new
facility represents a key endorsement of the wisdom of the public sector
investment in the project," said CEO, David Hughes."The Paranta contract is
an important step in ensuring that more of the drug development value chain is
retained locally." BPA, an industry-development company owned by the
Queensland State Government, put together the partnering deal with DSM, and is
currently project managing the final stages of the construction of the new
state-of-the-art facility in cooperation with DSM Biologics."

Financial terms were not disclosed.

Paranta Biosciences Ltd

Paranta Biosciences is an early stage drug development company committed to
the research, development and commercialization of recombinant human
follistatin for the treatment of respiratory diseases and conditions. The
company commenced operations as a private company in September 2010 and became
an unlisted public company in April 2011. Paranta Biosciences is based in
Melbourne, Australia. More information can be found at www.parantabio.com. 

DSM – Bright Science. Brighter Living.™

Royal DSM is a global science-based company active in health, nutrition and
materials. By connecting its unique competences in Life Sciences and Materials
Sciences DSM is driving economic prosperity, environmental progress and social
advances to create sustainable value for all stakeholders. DSM delivers
innovative solutions that nourish, protect and improve performance in global
markets such as food and dietary supplements, personal care, feed,
pharmaceuticals, medical devices, automotive, paints, electrical and
electronics, life protection, alternative energy and bio-based materials.
DSM's 22,000 employees deliver annual net sales of about € 9 billion. The
company is listed on NYSE Euronext. More information can be found at
www.dsmbiologics.com and http://www.dsm.com/pharma.

Forward-looking statements

This press release may contain forward-looking statements with respect to
DSM's future (financial) performance and position. Such statements are based
on current expectations, estimates and projections of DSM and information
currently available to the company. DSM cautions readers that such statements
involve certain risks and uncertainties that are difficult to predict and
therefore it should be understood that many factors can cause actual
performance and position to differ materially from these statements. DSM has
no obligation to update the statements contained in this press release, unless
required by law. The English language version of the press release is leading.

For more information:

Guy Tiene
Director, Marketing and Communications DSM Pharmaceutical Products
tel. +1 973 257 8160
email guy.tiene@dsm.com

Karen King
DSM Biologics
tel. +1 973 257 8427
email karen.king@dsm.com

SOURCE DSM Pharmaceutical Products

Website: http://www.dsm.com
Press spacebar to pause and continue. Press esc to stop.